Abeona Therapeutics Inc (ABEO) Q4 2025 Earnings Call Transcript
Abeona Therapeutics reported its Q4 2018 results, highlighting progress on its lead cell therapy EB-101 for recessive dystrophic epidermolysis bullosa (RDEB). The Phase 1/2 trial demonstrated continuous type VII collagen expression for over two years, a favorable safety profile, and durable wound healing. The company also detailed expansion of its Cleveland cGMP facility, now capable of treating up to 120 patients per year and scalable to ten suites. Additionally, Abeona showcased its AIM AAV vector platform with promising data for cystic fibrosis, Pompe, Fabry and retinal diseases, while reporting $85 million cash and a net loss of $1.19 per share for the year.
Cibus Inc (CBUS) Q4 2025 Earnings Call Transcript
Cibus reported a $9.9 million cash balance and a $22.3 million capital raise that extends its runway into late 2026. Operating expenses were trimmed by roughly $10 million, though the quarter posted a $31.9 million net loss. The company highlighted a $200 million royalty opportunity...
ION717 Trial Re-Opens with 3rd Dosing Regimen
Ionis Pharmaceuticals announced that its Phase 1/2a PrProfile trial of ION717, the first PrP‑lowering antisense oligonucleotide for symptomatic prion disease, has reopened with a third dosing regimen. The study, which enrolled 56 patients in 2024, will now recruit at three...
Light-Controlled Hydrogel Mimics Soft Human Tissue for More Realistic Cell Studies
Researchers at the University of Colorado Boulder have created a light‑controlled hydrogel that closely replicates the softness and viscoelastic behavior of human tissue. The material can be solidified or softened on demand using photopolymerization, allowing precise spatial control during 3‑D...
FDA Drug Safety Communication: Updated Drug Labels for Pioglitazone-Containing Medicines
The FDA has approved updated labeling for all pioglitazone‑containing medicines, adding a warning that use longer than one year may increase bladder cancer risk. Healthcare professionals are instructed not to prescribe pioglitazone to patients with active bladder cancer and to...
FDA Drug Safety Communication: FDA Approves Label Changes for Use of General Anesthetic and Sedation Drugs in Young Children
The FDA has approved label changes for general anesthetic and sedation drugs used in children under three, adding a warning that prolonged exposure—more than three hours or multiple procedures—may harm brain development. The revisions incorporate animal study data showing neuronal...
Frog-Cell 'Neurobots' Grow Self-Organized Nervous Systems and Alter Gene Activity
Researchers at the Wyss Institute have created the first “neurobots,” living robots built from frog embryonic cells that incorporate neuronal precursor cells to form self‑organizing nervous systems. The neurobots develop mature neurons that connect internally and extend processes to surface...
Millions of Protein Complexes Added to AlphaFold Database Shed Light on How Proteins Interact
A joint effort by EMBL‑EBI, Google DeepMind, NVIDIA and Seoul National University has added millions of AI‑predicted protein complex structures to the AlphaFold Database, marking the largest collection of such data to date. The release focuses on high‑confidence homodimers, delivering...
IDT Unveils NGS Portfolio
Integrated DNA Technologies (IDT) announced a new next‑generation sequencing (NGS) portfolio that includes the DNA EZ v2 library preparation kit, the xGen Exome v2 Hyb spike‑in panel, a 1,536‑member set of full‑length unique dual‑index adapters, and an upgraded whole‑genome sequencing system. The suite targets...
Illumina Launches Software for Multiomic Analysis
Illumina unveiled Illumina Connected Multiomics, a cloud‑based platform that unifies single‑cell, spatial transcriptomics, proteomics, and methylation data for large‑scale analysis. The system aggregates thousands of samples from Illumina and third‑party assays, delivering reproducible results through DRAGEN secondary analysis. AI‑driven tools...
FDA Clears Cepheid Xpert GI Multiplex PCR Test
Cepheid’s Xpert GI panel received FDA clearance, offering a multiplex PCR test that identifies 11 bacterial, viral, and parasitic gastrointestinal pathogens from a single stool sample. The assay delivers results in roughly 74 minutes and operates on the existing GeneXpert...
FDA Clears Copan PhenoMatrix Software
The U.S. Food and Drug Administration granted 510(k) clearance to Copan Group’s PhenoMatrix, an AI‑driven image‑assessment tool that runs on the WASPLab automation platform. Classified as a class II device, the software automatically sorts and evaluates bacterial culture plate images across...
Ultrasound-Activated Nanoparticles Breach Bacterial Biofilms
Scientists have engineered silica‑based nanoparticles that encapsulate rifampicin and release it only when exposed to low‑frequency ultrasound. The ultrasound both propels the particles through the protective matrix of bacterial biofilms and triggers cavitation that opens the particles, delivering the antibiotic...
AI and Genomics: A New Era of Personalized Medicine
Artificial intelligence is reshaping genomics by speeding up sequencing and uncovering patterns that traditional tools miss, enabling truly personalized medicine. AI models can predict disease risk, suggest optimal therapies, and guide tumor classification, especially in oncology and emerging mRNA vaccine...
Interfering in Induction of Bystander Senescence as an Approach to Senotherapy
Researchers have mapped how senescence spreads between human brain cell types via the senescence‑associated secretory phenotype (SASP). Using DNA‑damage‑induced cultures and conditioned‑media assays, they identified cell‑type‑specific SASP signatures that drive secondary senescence in neighboring astrocytes, endothelial cells, microglia, oligodendrocytes and...
How Synergy Spine Engineered Its New Cervical Disc for Mobility and Alignment
Synergy Spine Solutions secured FDA pre‑market approval for its Synergy Disc, the first artificial cervical disc that simultaneously improves spinal alignment and preserves full range of motion. The device features a patented interrupted‑articulation geometry that creates a low‑energy, lordotic position...
VIS-101 Shows Safety, Rapid Efficacy in Wet AMD
NovaBridge’s VIS‑101, a dual VEGF‑A and angiopoietin‑2 inhibitor, delivered rapid and durable efficacy in a phase 2a trial of 38 wet AMD patients in China. Participants receiving 3 mg or 6 mg doses achieved mean visual gains exceeding 10 ETDRS letters and central...
Structure Therapeutics Inc. (GPCR) Discusses Positive Topline Results From ACCESS II and Related Studies of Aleniglipron Oral GLP-1 Transcript
Structure Therapeutics announced positive topline data from its ACCESS II trial of aleniglipron, an oral small‑molecule GLP‑1 receptor agonist. The study demonstrated statistically significant reductions in HbA1c and weight loss comparable to injectable GLP‑1 therapies. Safety signals were mild, with few...
CytomX Surges on Positive Data for ‘Masked’ ADC in Colorectal Cancer
CytomX Therapeutics’ shares surged 66% after the company released expansion data from its Phase 1 study of Varseta‑M, a masked antibody‑drug conjugate targeting EpCAM in late‑stage colorectal cancer. The trial evaluated three dose levels, with the two highest doses achieving response...
Sun Pharma's Tildrakizumab Advances Into Psoriatic Arthritis as FDA Accepts sBLA
Sun Pharmaceutical's tildrakizumab (Ilumya) received FDA acceptance for a supplemental biologics license application to treat active psoriatic arthritis. The sBLA is backed by two Phase III INSPIRE studies involving more than 800 patients, which met primary endpoints with significant ACR20 improvements...
Chinese-Owned Syngenta to Build New £100m Bioscience Hub in UK
Chinese-owned agriscience leader Syngenta announced a £100 million investment to build a new bioscience hub, BioSTaR, at its Jealott’s Hill site in Berkshire. The centre will consolidate 300 scientists to develop biological pesticides and AI‑enabled crop protection technologies, with completion targeted...
This Hidden Immune Signal Could Change Cancer Therapy
Researchers have identified that a surface‑defensive molecule on cancer cells not only sends a “don’t‑eat‑me” signal but also conceals an “eat‑me” cue that would normally trigger immune clearance. A newly engineered antibody can disrupt this masking interaction, making tumors visible...
Qlaris Bio Appoints New CEO Fred Guerard
Qlaris Bio announced that Fred Guerard, PharmD, will serve as its president and chief executive officer, succeeding co‑founder Thurein Htoo. The biotech is moving its lead candidate, QLS‑111, into Phase 3 trials for open‑angle glaucoma and ocular hypertension. Guerard arrives with...
Bimekizumab Does Not Increase Depression, Suicide Risk Vs. Other Psoriasis Biologics
A retrospective TriNetX analysis of 1,691 psoriasis patients compared bimekizumab with IL‑23 inhibitors and found no greater incidence of new‑onset depression, suicidal ideation, or related medication use. Over a two‑year follow‑up, the combined psychiatric event rate was 4.9% for bimekizumab...
Computational Model Predicts Telomere Length From Routine Biopsy Slide Images
Researchers at Sanford Burnham Prebys unveiled TLPath, a machine‑learning model that infers telomere length from routine histopathology slides. The system was trained on 5,263 whole‑slide images covering 18 organs from 919 individuals and can predict telomere shortening in 11 tissue...
Placenta: Century‑Old Medical Resource Beyond Waste
Actually yes. The placenta has been used in medicine for over 100 years. The amniotic membrane is used in eye surgery for corneal reconstruction. It's used as a graft for burn treatment and wound healing. It's used in dental and orthopedic...
Seeking Examples of Overly Negative Biotech Trade Press
Will ask colleagues to respond because I haven’t been tracking all the tickers. Pls reply with examples of biotech trade press being called too negative
NeoGenomics’ PanTracer LBx Receives Medicare Coverage, Expanding Access to Comprehensive Liquid Biopsy Profiling
NeoGenomics announced that its PanTracer™ LBx liquid biopsy test has received Medicare coverage under CMS’s MolDX program. The CLIA‑certified assay profiles more than 500 genes, including MSI and blood‑tumor mutational burden, with a seven‑day turnaround. Coverage allows Medicare beneficiaries to...
Broken Chromosomes Repaired with Fragments Spark Cancer‑driving Mutations
Researchers at Cardiff University found that severe DNA mutations called chromoanasynthesis happen when broken chromosomes are repaired using small DNA fragments, causing chaotic duplications that can drive cancer and genetic diseases. 🧬https://t.co/Q9j2hRezTs
Judge Stalls Kennedy Childhood Vaccine Overhaul Meeting
Kennedy childhood vaccine overhaul stalled by judge The next meeting of the Advisory Committee on Immunization Practices was scheduled for this week, but has been postponed due to the ruling https://t.co/0cUIXEVgyV
Sentynl Therapeutics Enters Licensing Agreement with PRG S&T to Advance Progerinin
Sentynl Therapeutics, a Zydus Lifesciences subsidiary, has licensed Progerinin, an oral small‑molecule candidate for Hutchinson‑Gilford Progeria Syndrome, from PRG S&T. The agreement grants Sentynl full development rights, making Progerinin its second HGPS therapy and giving it orphan‑drug status from the FDA....
Methionine Restriction Cuts Alzheimer Pathology via FGF21 Signaling
A study in Alzheimer's & Dementia found that late-life methionine restriction reduces Alzheimer’s pathology and neuroinflammation in mice by activating the liver–brain FGF21–FGFR1 signaling pathway, independent of metabolic improvements. 🧠 https://t.co/A9kEqNv8pO
Semaglutide Boosts Metabolism, Reduces Anxiety in Obese Mice
Beyond the Weight Loss: The Effects of Semaglutide on Standard and Diet-Induced Obese Mice 🤔"..semaglutide improved glucose metabolic health inboth diet groups..while chronic semaglutide treatment appeared to exertanxiolytic effects in obese mice, opposit[e] effects were observed in lean animals.." https://t.co/doU6EkwT7z
Six Biotech Companies Advancing the Next Generation of Prostate Cancer Therapies
Six biotech firms are pushing next‑generation prostate‑cancer therapies through late‑stage trials and financing milestones. Candel Therapeutics secured a $100 million royalty deal to fund aglatimagene’s launch, while Coherus Oncology closed a $50.1 million offering and partnered with J&J for a CCR8 antibody...
FDA Urges IRB Overhaul to Match China's 60‑day Trials
FDA commissioner Makary at a CMS conference today in Baltimore calls for “big and different” IRB reforms to catch China's speedy trial starts - pre-IND phase can run 380 days in the US, he said, while China is pushing for...
CytomX Jumps 66% on Promising Colorectal ADC Data
CytomX surges on positive data for ‘masked’ ADC in colorectal cancer https://t.co/PxQMISvyri by @Lilah_Alvarado $CTMX + 66%
Lebrikizumab Delivered Significant Skin Clearance and Improved Disease Severity in Children With Moderate-to-Severe Atopic Dermatitis
Almirall reported that lebrikizumab met both co‑primary endpoints in the Phase 3 ADorable‑1 trial, with 63% of pediatric participants achieving EASI‑75 and 44% attaining clear or almost clear skin (IGA 0/1) after 16 weeks. Key secondary outcomes showed significant itch reduction, higher...
Structure's GLP-1 Pill Shows Best-in-Class Obesity Results
Structure’s GLP-1 pill shows ‘best-in-class’ potential in obesity trial https://t.co/j0fzAg6GRV @ByJonGardner $GPCR $LLY $NVO $AZN $MRK #obesity
Multi-Ancestry Polygenic Score Predicts T2D, Obesity, GLP‑1 Need
A polygenic risk score that predicts Type 2 diabetes, obesity, and likelihood for requiring a GLP-1 drug. Across 6 ancestries. https://t.co/5hTVv8kqlK https://t.co/IgXhx8vFA6
BIO on the American Road in Puerto Rico: ‘Medicine Cabinet’ Ready to Reshore
BIO President John F. Crowley toured Puerto Rico in March, highlighting the island’s role as “America’s Medicine Cabinet.” The territory already ships nearly one‑fifth of U.S. drug exports and accounts for about 30% of its GDP. Recent announcements from Amgen...
Biotech IPOs Falter as Companies Pull Planned Listings
16March: Which companies recently withdrew their planned IPOs? And how much have the stocks of this year's #biotech IPOs risen or fallen this year? Read about the IPO market plus updates on $BNTX, $IXHL, and $INKT in my latest StockWatch...
AI-Driven Digital Biology Delivers Custom Cancer Vaccine for Dog
The era of digital biology, exemplified by making a bespoke and effective vaccine for cancer in a dog, is taking off. Access to the AI-Coscientist. A new feature @NatureMedicine https://t.co/AR9lqne7E1
What Determines Success in Complex MASH Clinical Research Today?
Recent FDA approvals of resmetirom and semaglutide have shifted MASH care from a treatment‑void to a therapeutic reality, prompting sponsors to redesign trial endpoints and enrollment strategies. Non‑invasive diagnostic tools are emerging as potential primary endpoints, reducing reliance on liver...
Aged Blood Stem Cell Mutations Drive Aortic Aneurysm Growth
Just weeks ago we didn't know that mutant clones of our aged blood stem cells could be linked to expansion of an aortic aneurysm. No less how. And so much more https://t.co/YuEmJPkdg2 https://t.co/qQq2dgAfWf
Sarepta Tests Elevidys Safety, Sana
Sarepta tests new Elevidys safeguards; Sana advances diabetes cell therapy https://t.co/hkixuANCCV $SRPT $SANA $INO $BAYRY #biotech
Malicious Metals Muddy Fragment-to-Lead Optimization
Researchers at the Cleveland Clinic pursued fragment‑based inhibitors of SARS‑CoV‑2 NSP14, a viral exonuclease essential for replication and immune evasion. Initial crystal‑guided merges appeared active in a biochemical assay, prompting optimism about fragment linking. Subsequent resynthesis and rigorous purification revealed...
Two Publications Highlight Clinical Utility of Signatera™ in Anal and Rectal Cancers
Natera announced two peer‑reviewed studies demonstrating the clinical utility of its personalized ctDNA assay, Signatera, in anal squamous cell carcinoma and locally advanced rectal cancer. In the ASCC cohort of 84 patients, baseline negativity or clearance of ctDNA during chemoradiotherapy...
Module 2 Quiz
Drug Hunter’s online curriculum includes a Module 2 Quiz that tests learners on target identification and validation concepts. The quiz is part of a broader course designed for drug discovery professionals and requires full platform access via subscription or sign‑in. It...
Elevara Begins Phase 2b Trial of ELV001 in Rheumatoid Arthritis
Elevara Medicines has dosed the first patient in its phase 2b START‑SYNERGY trial, testing the oral CDK4/6 inhibitor ELV001 in rheumatoid arthritis patients who have failed methotrexate and TNF inhibitors. The randomized, placebo‑controlled study will enroll about 180 participants across nine...
Photonics and Nanotech Could Spot Cancer Signals 5 to 8 Years Earlier
Researchers at the University of Illinois Urbana‑Champaign have engineered a photonic‑nanomaterial platform that senses microRNA and DNA signatures linked to cancer up to five to eight years before conventional diagnostics can. The system leverages photonic crystal grating resonance and nano‑assemblies...